MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx

A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid.

Episode metadata supplied by the publisher feed · Published Jun 12, 2026

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx

0:00 13:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 13 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on June 12, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!